Cargando…

A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy d glucose in treating COVID-19

PURPOSE: In the wake of SARS-CoV-2’s global spread, human activities from health to social life to education have been affected. Favipiravir and Molnupiravir exhibited novel hexokinase inhibition and we discuss advantages of this property in their COVID-19 inhibition potential. METHODS: This paper d...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulkarni, Prajakta, Padmanabhan, Sriram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128636/
https://www.ncbi.nlm.nih.gov/pubmed/35608787
http://dx.doi.org/10.1007/s10529-022-03259-6
_version_ 1784712593696358400
author Kulkarni, Prajakta
Padmanabhan, Sriram
author_facet Kulkarni, Prajakta
Padmanabhan, Sriram
author_sort Kulkarni, Prajakta
collection PubMed
description PURPOSE: In the wake of SARS-CoV-2’s global spread, human activities from health to social life to education have been affected. Favipiravir and Molnupiravir exhibited novel hexokinase inhibition and we discuss advantages of this property in their COVID-19 inhibition potential. METHODS: This paper describes molecular docking data of human hexokinase II with Favipiravir, Cyan 20, Remdesivir, 2DG, and Molnupiravir along with hexokinase inhibition assays. RESULTS: Favipiravir, an antiviral drug previously cleared for treating the flu and ebola, has shown some promise in early trials to treat COVID-19. We observed potent human hexokinase inhibiting potential of Favipiravir (50%) as against 4% and merely 0.3% hexokinase inhibition with Molnupiravir and 2 Deoxy d glucose at 0.1 mM concentration supported by molecular docking studies. CONCLUSION: Favipiravir could continue to be part of the COVID-19 treatment regimen due to its resistance to host esterases, hexokinase inhibition potential and proven safety through human trials.
format Online
Article
Text
id pubmed-9128636
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-91286362022-05-25 A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy d glucose in treating COVID-19 Kulkarni, Prajakta Padmanabhan, Sriram Biotechnol Lett Original Research Paper PURPOSE: In the wake of SARS-CoV-2’s global spread, human activities from health to social life to education have been affected. Favipiravir and Molnupiravir exhibited novel hexokinase inhibition and we discuss advantages of this property in their COVID-19 inhibition potential. METHODS: This paper describes molecular docking data of human hexokinase II with Favipiravir, Cyan 20, Remdesivir, 2DG, and Molnupiravir along with hexokinase inhibition assays. RESULTS: Favipiravir, an antiviral drug previously cleared for treating the flu and ebola, has shown some promise in early trials to treat COVID-19. We observed potent human hexokinase inhibiting potential of Favipiravir (50%) as against 4% and merely 0.3% hexokinase inhibition with Molnupiravir and 2 Deoxy d glucose at 0.1 mM concentration supported by molecular docking studies. CONCLUSION: Favipiravir could continue to be part of the COVID-19 treatment regimen due to its resistance to host esterases, hexokinase inhibition potential and proven safety through human trials. Springer Netherlands 2022-05-24 2022 /pmc/articles/PMC9128636/ /pubmed/35608787 http://dx.doi.org/10.1007/s10529-022-03259-6 Text en © The Author(s), under exclusive licence to Springer Nature B.V. 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Research Paper
Kulkarni, Prajakta
Padmanabhan, Sriram
A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy d glucose in treating COVID-19
title A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy d glucose in treating COVID-19
title_full A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy d glucose in treating COVID-19
title_fullStr A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy d glucose in treating COVID-19
title_full_unstemmed A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy d glucose in treating COVID-19
title_short A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy d glucose in treating COVID-19
title_sort novel property of hexokinase inhibition by favipiravir and proposed advantages over molnupiravir and 2 deoxy d glucose in treating covid-19
topic Original Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128636/
https://www.ncbi.nlm.nih.gov/pubmed/35608787
http://dx.doi.org/10.1007/s10529-022-03259-6
work_keys_str_mv AT kulkarniprajakta anovelpropertyofhexokinaseinhibitionbyfavipiravirandproposedadvantagesovermolnupiravirand2deoxydglucoseintreatingcovid19
AT padmanabhansriram anovelpropertyofhexokinaseinhibitionbyfavipiravirandproposedadvantagesovermolnupiravirand2deoxydglucoseintreatingcovid19
AT kulkarniprajakta novelpropertyofhexokinaseinhibitionbyfavipiravirandproposedadvantagesovermolnupiravirand2deoxydglucoseintreatingcovid19
AT padmanabhansriram novelpropertyofhexokinaseinhibitionbyfavipiravirandproposedadvantagesovermolnupiravirand2deoxydglucoseintreatingcovid19